These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 8302305)

  • 1. Nigral degeneration in Parkinson's disease.
    Rinne JO
    Mov Disord; 1993; 8 Suppl 1():S31-5. PubMed ID: 8302305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nigral degeneration in Parkinson's disease in relation to clinical features.
    Rinne JO
    Acta Neurol Scand Suppl; 1991; 136():87-90. PubMed ID: 1801543
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selegiline can mediate neuronal rescue rather than neuronal protection.
    Tatton WG
    Mov Disord; 1993; 8 Suppl 1():S20-30. PubMed ID: 8302304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
    Youdim MB; Riederer P
    Mov Disord; 1993; 8 Suppl 1():S8-13. PubMed ID: 8302308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selegiline (deprenyl) treatment and death of nigral neurons in Parkinson's disease.
    Rinne JO; Röyttä M; Paljärvi L; Rummukainen J; Rinne UK
    Neurology; 1991 Jun; 41(6):859-61. PubMed ID: 1904564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
    Olanow CW
    Mov Disord; 1993; 8 Suppl 1():S1-7. PubMed ID: 8302302
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antioxidant mechanism and protection of nigral neurons against MPP+ toxicity by deprenyl (selegiline).
    Wu RM; Mohanakumar KP; Murphy DL; Chiueh CC
    Ann N Y Acad Sci; 1994 Nov; 738():214-21. PubMed ID: 7832430
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenesis and animal studies of Parkinson's disease.
    Oertel WH; Kupsch A
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):323-32. PubMed ID: 8507901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Type B monoamine oxidase and neurotoxins.
    Naoi M; Maruyama W
    Eur Neurol; 1993; 33 Suppl 1():31-7. PubMed ID: 8375430
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Big first scored with nerve diseases.
    Lewin R
    Science; 1989 Aug; 245(4917):467-8. PubMed ID: 2502841
    [No Abstract]   [Full Text] [Related]  

  • 13. Early signs of neuronal apoptosis in the substantia nigra pars compacta of the progressive neurodegenerative mouse 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine/probenecid model of Parkinson's disease.
    Novikova L; Garris BL; Garris DR; Lau YS
    Neuroscience; 2006 Jun; 140(1):67-76. PubMed ID: 16533572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transferrin receptor regulation in Parkinson's disease and MPTP-treated mice.
    Mash DC; Sanchez-Ramos J; Weiner WJ
    Adv Neurol; 1993; 60():133-9. PubMed ID: 8420130
    [No Abstract]   [Full Text] [Related]  

  • 15. Parkinson's disease: current view.
    Langston JW
    Am Fam Physician; 1987 Mar; 35(3):201-6. PubMed ID: 3103408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship among nigrostriatal denervation, parkinsonism, and dyskinesias in the MPTP primate model.
    Di Monte DA; McCormack A; Petzinger G; Janson AM; Quik M; Langston WJ
    Mov Disord; 2000 May; 15(3):459-66. PubMed ID: 10830409
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of dopamine autoxidation, hydroxyl radical generation, and calcium overload in underlying mechanisms involved in MPTP-induced parkinsonism.
    Chiueh CC; Miyake H; Peng MT
    Adv Neurol; 1993; 60():251-8. PubMed ID: 8380519
    [No Abstract]   [Full Text] [Related]  

  • 18. Are free radicals involved in the pathogenesis of idiopathic Parkinson's disease?
    Poirier J; Thiffault C
    Eur Neurol; 1993; 33 Suppl 1():38-43. PubMed ID: 8375431
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mechanisms of neuronal loss in Parkinson's disease: a neuroanatomical-biochemical perspective.
    Hornykiewicz O
    Clin Neurol Neurosurg; 1992; 94 Suppl():S9-11. PubMed ID: 1320533
    [TBL] [Abstract][Full Text] [Related]  

  • 20. R-(-)-deprenyl and parkinsonism.
    Yahr MD
    J Neural Transm Suppl; 1987; 25():5-12. PubMed ID: 3123605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.